Literature DB >> 35845328

Differential Impact of Central Venous Catheters versus Arteriovenous Fistulae on Quality of Life among Irish Haemodialysis Patients.

I Caoimhe Maguire1, Leonard D Browne1,2, Mina Dawood3, Fiona Leahy4, Maria C Ryan4, Eoin White2,5, Aidan O'Sullivan2,5,6, Leonard O'Sullivan2,5,6, Austin G Stack1,2,3.   

Abstract

Background: Arteriovenous fistulae (AVF) have superior clinical outcomes compared with central venous catheters (CVC) among patients undergoing hemodialysis (HD). Yet, there is increasing recognition that health-related quality of life (HRQoL) may be more important to patients than survival and that differences may exist between AVF and CVCs in this regard. This study compared HRQoL between AVF and CVC in an Irish cohort.
Methods: We conducted a cross-sectional survey among prevalent patients undergoing hemodialysis (N=119) dialyzing with either an AVF or CVC at a regional program. The Short Form 36 (SF-36) and a validated Vascular Access Questionnaire (SF-VAQ) compared QoL between AVF and CVC in domains of physical functioning, social functioning, and dialysis complications. Multivariable logistic regression compared differences between groups for outcomes of physical functioning, social functioning, and dialysis complications expressed as adjusted odds ratios and 95% CI.
Results: Mean age was 66.6 years; 52% were using an AVF and 48% had a CVC. Patients dialyzing with an AVF were more satisfied with their access when asked directly (6.2 versus 5.0; P<0.01). Physical functioning scores for bleeding, swelling, and bruising were significantly higher for AVF than CVC (P=0.001, P=0.001, and P<0.001, respectively). In contrast, patients with a CVC reported greater difficulties in bathing and showering than those using an AVF (4.4 versus 2.0; P<0.001), whereas patients with an AVF expressed greater concerns with physical appearances. Compared with AVF, CVC users were less likely to report difficulties in physical functioning (OR=0.35; 95% CI, 0.12 to 0.94; P=0.04) but more likely to report dialysis complications (OR=1.94; 95% CI, 0.69 to 5.87; P=0.22). Conclusions: Vascular access contributes to HRQoL in hemodialysis. CVCs are associated with fewer difficulties from bleeding and bruising but greater negative effect on social activities, including bathing and showering. Overall, patients with a CVC had lower dissatisfaction scores than patients with an AVF when all three domains were added. Innovation in vascular access design and engineering may confer benefits and improve patient comfort on HD.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  AVF; CVC; ESKD; SF-36; SF-VAQ; dialysis; health-related quality of life

Mesh:

Year:  2022        PMID: 35845328      PMCID: PMC9255886          DOI: 10.34067/KID.0006622021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  29 in total

1.  The Short Form 36 (SF-36) Health Survey: normative data for the Irish population.

Authors:  C Blake; M B Codd; Y M O'Meara
Journal:  Ir J Med Sci       Date:  2000 Jul-Sep       Impact factor: 1.568

2.  Trends in US Vascular Access Use, Patient Preferences, and Related Practices: An Update From the US DOPPS Practice Monitor With International Comparisons.

Authors:  Ronald L Pisoni; Lindsay Zepel; Friedrich K Port; Bruce M Robinson
Journal:  Am J Kidney Dis       Date:  2015-02-07       Impact factor: 8.860

3.  Renal Association Clinical Practice Guideline on vascular access for haemodialysis.

Authors:  Richard Fluck; Mick Kumwenda
Journal:  Nephron Clin Pract       Date:  2011-05-06

4.  KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.

Authors:  Charmaine E Lok; Thomas S Huber; Timmy Lee; Surendra Shenoy; Alexander S Yevzlin; Kenneth Abreo; Michael Allon; Arif Asif; Brad C Astor; Marc H Glickman; Janet Graham; Louise M Moist; Dheeraj K Rajan; Cynthia Roberts; Tushar J Vachharajani; Rudolph P Valentini
Journal:  Am J Kidney Dis       Date:  2020-03-12       Impact factor: 8.860

5.  Barriers to optimal vascular access for hemodialysis.

Authors:  Robert S Brown
Journal:  Semin Dial       Date:  2020-10-08       Impact factor: 3.455

6.  Evolution of Vascular Access Use among Incident Patients during the First Year on Hemodialysis: A National Cohort Study.

Authors:  Wael F Hussein; Gasim Ahmed; Leonard D Browne; William D Plant; Austin G Stack
Journal:  Kidney360       Date:  2021-04-22

7.  Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Donna L Mapes; Antonio Alberto Lopes; Sudtida Satayathum; Keith P McCullough; David A Goodkin; Francesco Locatelli; Shunichi Fukuhara; Eric W Young; Kiyoshi Kurokawa; Akira Saito; Jürgen Bommer; Robert A Wolfe; Philip J Held; Friedrich K Port
Journal:  Kidney Int       Date:  2003-07       Impact factor: 10.612

Review 8.  Should a fistula first policy be revisited in elderly haemodialysis patients?

Authors:  Carlo Lomonte; Carlo Basile; Sandip Mitra; Christian Combe; Adrian Covic; Andrew Davenport; Dimitrios Kirmizis; Daniel Schneditz; Frank van der Sande
Journal:  Nephrol Dial Transplant       Date:  2019-10-01       Impact factor: 5.992

9.  Hemodialysis Infection Prevention Protocols Ontario-Shower Technique (HIPPO-ST): A Pilot Randomized Trial.

Authors:  S Daisy Kosa; Amiram Gafni; Andrew A House; JulieAnn Lawrence; Louise Moist; Bharat Nathoo; Paul Tam; Alicia Sarabia; Lehana Thabane; George Wu; Charmaine E Lok
Journal:  Kidney Int Rep       Date:  2016-11-08

10.  Incidence of catheter-related complications in patients with central venous or hemodialysis catheters: a health care claims database analysis.

Authors:  Pavel Napalkov; Diana M Felici; Laura K Chu; Joan R Jacobs; Susan M Begelman
Journal:  BMC Cardiovasc Disord       Date:  2013-10-16       Impact factor: 2.298

View more
  1 in total

1.  Analysis of Nursing Effect of Comprehensive Nursing Intervention on Hemodialysis Patients with Uremia.

Authors:  Lanfang Hu; Yanting Ma; Lihong Wang; Yapping Dai
Journal:  Contrast Media Mol Imaging       Date:  2022-09-26       Impact factor: 3.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.